US006410729B1

(12) **United States Patent**
Spohr et al.

(10) **Patent No.: US 6,410,729 B1**
(45) **Date of Patent: Jun. 25, 2002**

(54) **SUBSTITUTED PYRIMIDINE COMPOUNDS AND METHODS OF USE**

(75) Inventors: **Ulrike D. Spohr**; **Michael J. Malone**, both of Boulder; **Nathan B. Mantlo**, Lafayette, all of CO (US)

(73) Assignee: **Amgen Inc.**, Thousand Oaks, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/598,740**

(22) Filed: **Jun. 21, 2000**

Related U.S. Application Data

(63) Continuation of application No. 08/984,774, filed on Dec. 4, 1997, now abandoned, which is a continuation-in-part of application No. 08/976,054, filed on Nov. 21, 1997, now abandoned.

(60) Provisional application No. 60/032,128, filed on Dec. 5, 1996, and provisional application No. 60/050,950, filed on Jun. 13, 1997.

(51) **Int. Cl.**[7] **C07D 239/02**; C07D 239/12; C07D 239/22; A61K 31/515

(52) **U.S. Cl.** **544/320**; 321/325; 514/269; 514/275

(58) **Field of Search** 514/269, 275; 544/320, 321, 325

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,772,288	A	*	11/1973	Hardtmann et al.	260/251
3,929,807	A		12/1975	Fitzi	260/294.8
4,438,117	A	*	3/1984	Cherkofsky et al.	
4,578,459	A	*	3/1986	Durant et al.	544/8
4,973,690	A		11/1990	Rempfler et al.	544/279
4,990,512	A		2/1991	Perrior et al.	514/269
5,077,142	A	*	12/1991	Sakon et al.	
5,250,530	A		10/1993	Giencke et al.	514/256
5,298,481	A		3/1994	Tice	504/242
5,300,477	A		4/1994	Tice	504/242
5,366,982	A		11/1994	Dereu et al.	514/340
5,434,157	A		7/1995	Wierenga et al.	514/272
5,492,915	A		2/1996	Dereu et al.	514/311
5,518,994	A		5/1996	Kawamura et al.	504/242
6,096,753	A	*	8/2000	Spohr et al.	514/269

FOREIGN PATENT DOCUMENTS

DE	1271116		6/1968
DE	3319843		12/1984
DE	2056407		5/1991
DE	1271116	*	6/1998
EP	039051		11/1981
EP	0130046		1/1985
WO	9202513	*	2/1992
WO	WO 92/10190		6/1992
WO	WO 92/10498		6/1992
WO	WO 92/12154		7/1992
WO	WO 93/14081		7/1993
WO	WO 92/02513		2/1995
WO	WO 95/35304		12/1995
WO	WO 96/03387		2/1996
WO	WO 96/21452		7/1996
WO	WO 96/21654		7/1996
WO	WO 96/24584		8/1996
WO	WO 97/12876		4/1997
WO	WO 97/16442		5/1997
WO	9733883	*	6/1997
WO	WO 97/33883		9/1997
WO	WO 97/38992		10/1997
WO	9824780	*	6/1998

OTHER PUBLICATIONS

Takahashi et al., Heterocycles, vol. 22,# 3 pp. 581–584, Mar. 1984.*
Bennett et al.;"J.Med.Chem.";21/7,623–28*1978).*
Baracos et al;. New Eng. J. Med., 308, 553 (1983).
Benneche et al., Acta Chem Scand. B 42, 384–389 (1988).
Bennett et al., J. Org. chem. 42, 221–225 (1977).
Berge et al., J. Pharm. Sci. 66, 1 (1977).
Beutler et. al., J. Immunol. 135, 3969 (1985).
Beyaert et al., EMBO Journal 1996, vol. 15, p 1914–23.
Brahn et al., Lymphokine Cytokine Res. 11, 253 (1992).
Bredereck et al., Chem Ber. 101, 41–50 (1968).
Bredereck et. al., Chem. Ber. 97, 3407–3417 (1964).
Brown, D. J., Heterocyclic Compounds: the Pyrimidines, Chapter 3, 1994, John Wiley & Sons.
Chandrasekhar et al., Clinical Immunol. Immunopathol. 55, 382 (1990).
Clouse et al., J. Immunol. 142, 431 (1989).
Cooper, Clin. Exp. Immunol. 89, 244 (1992).
Courtenay, J. S., Nature (1980), vol. 283, p 666.
Davies et al., J.Chem.Soc., Chem.Commun., 1153 (1993).
Dey et al., Tetrahedron, vol. 51, No. 27, pp. 7459–7468 (1995).
Dinarello, Eur. Cytokine Netw. 5, 517–531 (1994).
Efimovsky and Rumpf, Bull. Soc. Chim. FR. 648–649 (1954).
Firestein, Am. J. Pathol. 140, 1309 (1992).
Folks et al., J. Immunol. 136, 40 (1986).
Gallagher et al., Biorg. Med. Chem. Lett. 1995, 1171–1176.
Ife et al., Bioorg. Med. Chem. Lett. 5, 543 (1995).
Joosten et al, Arthritis & Rheumatism 39:797–809 (1996).
Kabbe, Lieb. Ann. Chem. 704, 144 (1967).

(List continued on next page.)

Primary Examiner—Mukund J. Shah
Assistant Examiner—Sudhaker B. Patel
(74) *Attorney, Agent, or Firm*—Frank S. Ungemach; Stuart L. Watt

(57) **ABSTRACT**

Selected novel substituted pyrimidine compounds are effective for prophylaxis and treatment of diseases, such as TNF-α, IL-1β, IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving inflammation, pain, diabetes and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

31 Claims, No Drawings